Alnylam Scientists Present Data from Multiple Programs at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 15, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its scientists will present data from multiple research, pre-clinical, and clinical programs at the 4th annual meeting of the Oligonucleotide Therapeutics Society (OTS) being held October 15-18, 2008 at the Harvard Medical School in Boston, Massachusetts.

"As is evident by a large number of quality presentations from our scientists and collaborators at this important meeting, we are making impressive progress on many fronts as we continue to advance the science of RNAi therapeutics," said Jack Schmidt, M.D., Alnylam's Chief Scientific Officer. "The new data demonstrate our continued success in optimizing small interfering RNAs and in achieving delivery of RNAi therapeutics. Further, our presentations highlight our progress in advancing RNAi therapeutics through pre-clinical and clinical development."

Muthiah Manoharan, Ph.D., Alnylam's Vice President, Drug Discovery will give a presentation titled "Unique Properties of 2'-Fluoro Modified siRNAs" as part of a session being held on Thursday, October 16, 2008 from 2:45 - 4:00 p.m. ET. In addition, Dr. Manoharan will chair a session titled "Oligonucleotide Chemistry and New Technologies" being held on the same day, from 4:30 - 6:45 p.m. ET.

Akshay Vaishnaw, M.D., Ph.D., Alnylam's Vice President, Clinical Research will give a presentation titled "A Phase II Trial of ALN-RSV01, an RNAi Therapeutic for Respiratory Syncytial Virus" as part of a session being held on Friday, October 17, 2008 from 2:30 - 4:10 p.m. ET.

Kevin Fitzgerald, Ph.D., Alnylam's Director of Research will give a presentation titled "Therapeutic RNAi Targeting PCSK9" as part of a session being held on Saturday, October 18, 2008 from 1:30 - 4:00 p.m. ET.

Alnylam scientists will also present several posters during the meeting, including:

-- "In Vivo delivery of lipophilic siRNAs to neurons and oligodendrocytes for treatment of CNS disorders;"

-- "Incorporation of Universal Bases or Mismatches in the Passenger Strand Can Increase the Potency of siRNA;"

-- "Polycationic Lipidoid Nanoparticle for the Delivery of siRNAs and Antagomirs;" and

-- "Polyethylene glycol (PEG) Conjugated siRNAs for In Vivo Delivery."

In addition, Peter S. Linsley, Ph.D., Regulus' Chief Scientific Officer will give a presentation titled "Therapeutic Targeting of MicroRNAs" as part of a session being held on Thursday, October 16, 2008 from 1:00 - 2:45 p.m. ET. Regulus Therapeutics is Alnylam's joint venture with Isis Pharmaceuticals focused on the discovery, development, and commercialization of microRNA therapeutics.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world's top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, and Huntington's disease. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, and Kyowa Hakko Kogyo. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam has established "RNAi 2010" which includes the company's plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development, and commercialization of microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, visit http://www.alnylam.com.

Alnylam Forward-Looking Statement

Various statements in this release concerning Alnylam's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the "Risk Factors" section of its most recent quarterly report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam does not assume any obligation to update any forward-looking statements.

Contact

Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207 (Investors)
or
Yates Public Relations
Kathryn Morris, 845-635-9828 (Media)

Posted: October 2008

View comments

Hide
(web2)